FACEPHI BIOMETRIA SA(EPA:ALPHI) stock Fundamental Analysis

Fundamental Rating

ALPHI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 99 industry peers in the Software industry. ALPHI has a bad profitability rating. Also its financial health evaluation is rather negative. ALPHI is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ALPHI has reported negative net income.

ALPHI had a positive operating cash flow in the past year.

In multiple years ALPHI reported negative net income over the last 5 years.

The reported operating cash flow has been mixed in the past 5 years: ALPHI reported negative operating cash flow in multiple years.

1.2 Ratios

ALPHI has a Return On Assets of -12.82%. This is in the lower half of the industry: ALPHI underperforms 72.73% of its industry peers.

With a Return On Equity value of -36.38%, ALPHI is not doing good in the industry: 73.74% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-12.82%
ROE	-36.38%
ROIC	N/A

ROA(3y)-3%

ROA(5y)-1.81%

ROE(3y)-6.86%

ROE(5y)-3.52%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALPHI's Gross Margin of 55.75% is on the low side compared to the rest of the industry. ALPHI is outperformed by 64.65% of its industry peers.

In the last couple of years the Gross Margin of ALPHI has declined.

The Profit Margin and Operating Margin are not available for ALPHI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	55.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-17.14%

GM growth 5Y-12.77%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALPHI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ALPHI has more shares outstanding

The number of shares outstanding for ALPHI has been increased compared to 5 years ago.

Compared to 1 year ago, ALPHI has a worse debt to assets ratio.

2.2 Solvency

ALPHI has an Altman-Z score of 0.61. This is a bad value and indicates that ALPHI is not financially healthy and even has some risk of bankruptcy.

ALPHI's Altman-Z score of 0.61 is on the low side compared to the rest of the industry. ALPHI is outperformed by 72.73% of its industry peers.

ALPHI has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.

ALPHI has a better Debt to Equity ratio (0.12) than 74.75% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Altman-Z	0.61

ROIC/WACCN/A

WACC8.03%

2.3 Liquidity

ALPHI has a Current Ratio of 0.69. This is a bad value and indicates that ALPHI is not financially healthy enough and could expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 0.69, ALPHI is doing worse than 81.82% of the companies in the same industry.

ALPHI has a Quick Ratio of 0.69. This is a bad value and indicates that ALPHI is not financially healthy enough and could expect problems in meeting its short term obligations.

ALPHI's Quick ratio of 0.69 is on the low side compared to the rest of the industry. ALPHI is outperformed by 80.81% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.69
Quick Ratio	0.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The earnings per share for ALPHI have decreased strongly by -81.67% in the last year.

The Revenue has grown by 12.10% in the past year. This is quite good.

The Revenue has been growing by 41.20% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)-81.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.78%

Revenue 1Y (TTM)12.1%

Revenue growth 3Y51.27%

Revenue growth 5Y41.2%

Sales Q2Q%19.95%

3.2 Future

ALPHI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 42.17% yearly.

Based on estimates for the next years, ALPHI will show a quite strong growth in Revenue. The Revenue will grow by 17.05% on average per year.

EPS Next Y45%

EPS Next 2Y44.91%

EPS Next 3Y42.17%

EPS Next 5YN/A

Revenue Next Year30.08%

Revenue Next 2Y25.67%

Revenue Next 3Y26.98%

Revenue Next 5Y17.05%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALPHI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Based on the Price/Forward Earnings ratio of 119.12, the valuation of ALPHI can be described as expensive.

Compared to the rest of the industry, the Price/Forward Earnings ratio of ALPHI indicates a slightly more expensive valuation: ALPHI is more expensive than 61.62% of the companies listed in the same industry.

When comparing the Price/Forward Earnings ratio of ALPHI to the average of the S&P500 Index (22.10), we can say ALPHI is valued expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	119.12

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ALPHI does not grow enough to justify the current Price/Earnings ratio.

A more expensive valuation may be justified as ALPHI's earnings are expected to grow with 42.17% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y44.91%

EPS Next 3Y42.17%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ALPHI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FACEPHI BIOMETRIA SA

EPA:ALPHI (3/7/2025, 7:00:00 PM)

2.43

-0.12 (-4.71%)

Chartmill FA Rating

GICS SectorInformation Technology

GICS IndustryGroupSoftware & Services

GICS IndustrySoftware

Earnings (Last)02-13 2025-02-13/amc

Earnings (Next)N/A N/A

Inst Owners18.62%

Inst Owner ChangeN/A

Ins Owners6.65%

Ins Owner ChangeN/A

Market Cap54.89M

Analysts82.86

Price Target1.83 (-24.69%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)-5.94%

PT rev (3m)6.45%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-1200%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	119.12
P/S	2.03
P/FCF	N/A
P/OCF	28.83
P/B	3.38
P/tB	13.08
EV/EBITDA	N/A

EPS(TTM)-0.26

EYN/A

EPS(NY)0.02

Fwd EY0.84%

FCF(TTM)-0.41

FCFYN/A

OCF(TTM)0.08

OCFY3.47%

SpS1.2

BVpS0.72

TBVpS0.19

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-12.82%
ROE	-36.38%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	55.75%
FCFM	N/A

ROA(3y)-3%

ROA(5y)-1.81%

ROE(3y)-6.86%

ROE(5y)-3.52%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-17.14%

GM growth 5Y-12.77%

F-Score3

Asset Turnover0.59

Health

		Industry Rank	Sector Rank
Debt/Equity	0.12
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	183.54%
Cap/Sales	41.31%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.69
Quick Ratio	0.69
Altman-Z	0.61

F-Score3

WACC8.03%

ROIC/WACCN/A

Cap/Depr(3y)169.83%

Cap/Depr(5y)192.18%

Cap/Sales(3y)22.62%

Cap/Sales(5y)21.88%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-81.67%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-6.78%

EPS Next Y45%

EPS Next 2Y44.91%

EPS Next 3Y42.17%

EPS Next 5YN/A

Revenue 1Y (TTM)12.1%

Revenue growth 3Y51.27%

Revenue growth 5Y41.2%

Sales Q2Q%19.95%

Revenue Next Year30.08%

Revenue Next 2Y25.67%

Revenue Next 3Y26.98%

Revenue Next 5Y17.05%

EBIT growth 1Y-264.95%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year157.1%

EBIT Next 3Y47.24%

EBIT Next 5Y34.7%

FCF growth 1Y-48.96%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y145.39%

OCF growth 3Y-15.88%

OCF growth 5Y27.63%

FACEPHI BIOMETRIA SA (ALPHI.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens